IL17A and psoriasis: The development and application of biologics, particularly monoclonal antibodies targeting specific inflammatory mediators such as tumor necrosis factor (TNF)-α, interleukin (IL)-17, IL-23, and IL-12/23, have fundamentally transformed the treatment landscape for moderate-to-severe psoriasis and its associated nail disease.